Study of EPI-7386 and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

1 1 1 1

What is this study about?

This clinical trial is focused on studying a type of prostate cancer known as metastatic castration-resistant prostate cancer. This is a form of prostate cancer that continues to grow and spread even when the amount of male hormones in the body is reduced to very low levels. The study is testing a new treatment approach that combines two medications: EPI-7386 and enzalutamide. EPI-7386 is a new drug being developed, while enzalutamide is an existing medication used to treat prostate cancer. The purpose of the study is to see if the combination of these two drugs is more effective than using enzalutamide alone.

Participants in the study will receive either the combination of EPI-7386 and enzalutamide or enzalutamide by itself. The study will be conducted in two phases. In the first phase, the focus will be on determining the safety and appropriate dosage of the combination treatment. In the second phase, the study will evaluate how well the combination works in treating the cancer compared to enzalutamide alone. Throughout the study, participants will be monitored for any side effects and changes in their health.

The study aims to provide valuable information on whether the combination of EPI-7386 and enzalutamide can offer a better treatment option for patients with metastatic castration-resistant prostate cancer. By comparing the effects of the combination treatment to enzalutamide alone, researchers hope to find a more effective way to manage this challenging form of cancer.

1 joining the study

Upon joining the study, the patient will begin participation in a clinical trial focused on metastatic castration-resistant prostate cancer.

The trial involves the use of two medications: EPI-7386 and enzalutamide.

2 medication administration

The patient will receive EPI-7386 in the form of a film-coated tablet and enzalutamide as a 40 mg soft capsule.

Both medications are taken orally.

3 phase 1 objectives

The initial phase aims to determine the safety and tolerability of EPI-7386 when combined with a fixed dose of enzalutamide.

This phase will also establish the recommended dose for the next phase.

4 phase 2 objectives

The second phase evaluates the effectiveness of the combination of EPI-7386 and enzalutamide compared to enzalutamide alone.

Safety assessments continue during this phase.

5 monitoring and assessments

Throughout the trial, the patient will undergo regular monitoring, including laboratory tests and imaging scans, to assess the response to treatment.

The patient’s health and any side effects will be closely observed.

6 completion of the trial

The trial is expected to conclude by September 30, 2026.

Upon completion, the patient’s participation in the study will end, and final assessments will be conducted.

Who Can Join the Study?

Must provide written consent approved by an ethics committee before any study procedures.
Serum testosterone levels must be 1.73 nmol/L (50 ng/dL) or lower.
If taking medications for bone health, like bisphosphonates or denosumab, the dose must be stable for at least 28 days before starting the study treatment.
Must have adequate organ function, which includes:
- Enough white blood cells and platelets, and a certain level of hemoglobin.
- Normal liver function tests, except for those with Gilbert’s Syndrome.
- Normal kidney function.
- Normal levels of a protein called albumin.
If capable of having children, must agree to use effective birth control methods and avoid donating sperm during the study and for 3 months after the last treatment dose.
Any side effects from previous treatments must have improved to a mild level.
Must be willing and able to follow the study protocol, including attending follow-up visits and exams.
Must be a male aged 18 years or older.
Must have confirmed prostate cancer without certain features like small cell or neuroendocrine characteristics.
Must have evidence of castration-resistant prostate cancer, which means the cancer continues to grow despite low testosterone levels.
Must have metastatic disease, meaning the cancer has spread to other parts of the body, confirmed by scans.
Must not have used second-generation anti-androgens before. Previous use of a drug called docetaxel in a specific setting is allowed.
Must show evidence of progressive disease, meaning the cancer is getting worse, based on specific criteria like rising PSA levels or new lesions on scans.
Must have an ECOG performance status of 0 or 1, indicating the ability to carry out daily activities with little or no assistance.
Must be undergoing ongoing androgen deprivation therapy or have had surgery to remove the testicles, with testosterone levels at a castrate level.

Who Cannot Join the Study?

Patients who have already received treatment with second-generation anti-androgens cannot participate. These are medications used to treat prostate cancer by blocking male hormones.
Only male patients are eligible for this study, so female patients cannot participate.
Patients who are part of a vulnerable population, which means they might have special needs or circumstances that require extra protection, are not eligible.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country
Comite Entreprise Paul Papin	Angers	France
Institut Gustave Roussy	Villejuif	France
Oncopole Claudius Regaud	Toulouse	France

Other Sites

Site Name	City	Country
Centre Hospitalier Universitaire De Poitiers	Poitiers	France
Hospital Universitario 12 De Octubre	Madrid	Spain
Grand Hopital De Charleroi	Charleroi	Belgium
Hospital Clinic De Barcelona	Barcelona	Spain
Institut de Cancérologie de l’Ouest	Saint-Herblain	France
Hospital Universitario Virgen De La Victoria	Malaga	Spain
Hmuzjfln Uiemjccsnxrvl Mudwqbo Dl Vhywuifevv	Santander	Spain
Ibwcrtdr Cwemwv Dnlnxjbgutttkdxqb	L'hospitalet De Llobregat	Spain
Iijajnmhl Cxnigto dx Ozljdbtcy (dgi Gfecikc &digito Hzzxxojn Jdfxj Tmlqat	Girona	Spain
Corvzc Hvgnhucqzop Unhxcfecxwcsq Haoord &pqncds Hscmeii dy Mhtt	Mons	Belgium
Cmavehpxr Uzgsauxnjivhom Sqaixcpzx	Woluwe-Saint-Lambert	Belgium
Ivyaalqf Rmsodgwx Dk Cgeetq Dp Mkcbaqscaxz	Montpellier	France
Cjpvjn Lxfj Bmxhgu	Lyon	France
Fqvhyvehq Prfx Lq Iujvxgkpewupb Bagbnpllk Dlg Hhbsjsle Usxqwjzvgdyli Lt Pgp	Madrid	Spain
Harxczgm Vdet dtblsvwd	Barcelona	Spain

Trial status

Country	Status	Recruitment Start
Belgium	Not recruiting	15.05.2024
France	Not recruiting	15.05.2024
Spain	Not recruiting	15.05.2024

Trial locations

Investigated drugs:

EPI-7386 is an experimental medication being studied for its potential to treat metastatic castration-resistant prostate cancer. It is being tested in combination with another medication to see if it can improve treatment outcomes for patients who have not previously received second-generation anti-androgens.

Enzalutamide is a medication used to treat prostate cancer. It works by blocking the effects of male hormones that can promote the growth of cancer cells. In this study, enzalutamide is used both alone and in combination with EPI-7386 to evaluate its effectiveness and safety in treating metastatic castration-resistant prostate cancer.

Metastatic castration-resistant prostate cancer – This is a type of prostate cancer that continues to grow and spread even when the amount of testosterone in the body is reduced to very low levels. It is characterized by the cancer’s ability to metastasize, or spread, to other parts of the body such as bones and lymph nodes. The disease progresses despite treatments that lower testosterone, which is a hormone that typically fuels prostate cancer growth. Over time, the cancer cells adapt and find ways to thrive even in the absence of testosterone. This condition is often associated with symptoms like bone pain and urinary issues due to the spread of cancer. The progression of the disease can vary, with some patients experiencing rapid advancement while others may have a slower course.

Trial ID:

2023-509336-25-00

Protocol code:

EPI-7386-CS-010

NCT ID:

NCT05075577

Trial Phase:

Human Pharmacology (Phase I) – Other

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study of EPI-7386 and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?